Patient presents with medication concerns

Mme B., a 60-year-old woman who recently retired, was diagnosed with hormone-dependent breast cancer three months after retiring. She has been undergoing treatment with tamoxifene for four months following a lumpectomy and radiotherapy. She has also stopped smoking since her cancer diagnosis and presented two prescriptions for renewal, one from her primary care physician and one from her oncologist, and appeared particularly fatigued and disheartened.

Pharmacist identifies drug interaction risk

The pharmacist was immediately concerned about a potential interaction between tamoxifene and certain antidepressants, including paroxetine, which could reduce the effectiveness of tamoxifene. Mme B. mentioned she had difficulty sleeping and was experiencing hot flashes, and her physician had suggested the antidepressant might help. The pharmacist verified the interaction through the dispensation software, which confirmed a risk of reduced efficacy of tamoxifene due to its metabolism by the CYP2D6 enzyme, inhibited by paroxetine.

Regulatory agencies warn against combination

Research confirmed that the National Agency for the Safety of Medicines and Health Products (ANSM) classified the combination of tamoxifene and paroxetine as "not recommended," similar to other CYP2D6 inhibitors like fluoxetine and duloxetine. The drug interaction database drugs.com also classified the combination as major. The National Cancer Institute (INCa) noted a 65-75% reduction in plasma levels of endoxifene, the active metabolite of tamoxifene, with CYP2D6 inhibitors such as paroxetine and fluoxetine.

Alternative medications considered

Alternatives to paroxetine were considered, including venlafaxine and citalopram, which are weaker CYP2D6 inhibitors. However, citalopram and escitalopram are known to prolong the QT interval on an electrocardiogram, a concern when used with tamoxifene. The ANSM does not classify venlafaxine as a substance that induces torsades de pointes, unlike citalopram and escitalopram.

Treatment choice reflects patient-specific factors

The choice of tamoxifene over aromatase inhibitors, such as anastrozole, letrozole, and exemestane, was considered, as the latter are typically preferred in postmenopausal women but carry a risk of bone loss. Tamoxifene, a selective estrogen receptor modulator, was chosen for Mme B. due to her low body weight and history of smoking, which are risk factors for osteoporosis. The Inci noted that antidepressants are sometimes used off-label to manage hot flashes, including paroxetine, citalopram, escitalopram, and venlafaxine.

Pharmacist intervenes and documents change

The pharmacist contacted Mme B.'s physician, Dr. R., to discuss the potential interaction and suggest alternatives. Dr. R. agreed to switch the prescription from paroxetine to venlafaxine LP 75 mg, one tablet per day. The pharmacist documented the medication interaction on the Act-IP pharmacy platform, noting the interaction as "not recommended" by ANSM and the drug characteristics summaries, and the intervention as a change from paroxetine to venlafaxine after consultation with the physician.

Case highlights importance of medication review

The case was based on a real situation reported by the French Society of Clinical Pharmacy (SFPC), which has developed a coding and documentation tool for medication interventions. The SFPC provides information on its website, sfpc.eu, and in the "Pharmaceutical Intervention" training booklet published in Le Moniteur des pharmacies.